AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15121490 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K-depleted diet
Number of subjects: 12
Study 15121490 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K-enriched diet
Number of subjects: 12
Study 11157557 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with involuntary movements
Number of subjects: 35
Study 11157557 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study 9129851 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous enalapril
Number of subjects: 60
Study 9129851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9129851 — intervention group
Group type: COMPARATOR
Intervention: Control (no ST-depression)
Number of subjects: 60
Study 9129851 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with long-lasting ST-depression (> 60 min)
Number of subjects: 60
Study 9129851 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with long-lasting ST-depression
Number of subjects: 60
Study 8186157 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol
Number of subjects: 20
Study 8186157 — intervention group
Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 20
Study 3063043 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antibiotics (gentamicin 160 mg + metronidazole 400 mg)
Number of subjects: 79
Study 3063043 — intervention group
Group type: COMPARATOR
Intervention: Systemic antibiotics only (gentamicin 80 mg + metronidazole 500 mg intravenously)
Number of subjects: 79
Study 3063043 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antibiotics
Number of subjects: 79
Study 29340815 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal tunneling endoscopic resection (STER)
Number of subjects: 58
Study 29340815 — intervention group
Group type: COMPARATOR
Intervention: Video-assisted thoracoscopic enucleation (VATE)
Number of subjects: 58
Study 26662171 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous nephrostomy
Number of subjects: 107
Study 26662171 — intervention group
Group type: COMPARATOR
Intervention: Emergent retrograde ureteroscopic management
Number of subjects: 107
Study 24618483 — intervention group
Group type: EXPERIMENTAL
Intervention: Citicoline plus patching
Number of subjects: 0
Study 24618483 — intervention group
Group type: COMPARATOR
Intervention: Patching alone
Number of subjects: 0
Study 23434724 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 23434724 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 0
Study 21175435 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 50
Study 21175435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 17581533 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (0, 0.0625, 0.125, 0.187, and 0.250 mg/70 kg)
Number of subjects: 8
Study 17581533 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (0, 0.125, 0.5, 2, and 8 mg/70 kg)
Number of subjects: 8
Study 17581533 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin (0, 3.125, 6.25, 12.5, and 25 mg/70 kg)
Number of subjects: 8
Study 17581533 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0, 6.25, 12.5, 25, and 50 mg/70 kg)
Number of subjects: 8
Study 17581533 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (0, 6.25, 12.5, 25, and 50 mg/70 kg)
Number of subjects: 8
Study 16493216 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral electrovapor resection of the prostate (TUVRP)
Number of subjects: 76
Study 16493216 — intervention group
Group type: COMPARATOR
Intervention: Standard transurethral resection of the prostate (TURP)
Number of subjects: 76
Study 12577135 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with AAAs
Number of subjects: 54
Study 12577135 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with popliteal aneurysms
Number of subjects: 54
Study 12577135 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with AAAs
Number of subjects: 54
Study 12577135 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (age- and gender-matched)
Number of subjects: 54
Study 10840174 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK‐4 (50 microg)
Number of subjects: 80
Study 10840174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 9342915 — intervention group
Group type: EXPERIMENTAL
Intervention: Se-enriched yeast (200 micrograms Se/day)
Number of subjects: 1312
Study 9342915 — intervention group
Group type: COMPARATOR
Intervention: Low-Se yeast placebo
Number of subjects: 1312
Study 8458140 — intervention group
Group type: EXPERIMENTAL
Intervention: Active stimulators
Number of subjects: 40
Study 8458140 — intervention group
Group type: COMPARATOR
Intervention: Dummy stimulators (Control)
Number of subjects: 40
Study 3767146 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous propafenone, 2 mg/kg body weight
Number of subjects: 20
Study 3767146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31895785 — intervention group
Group type: EXPERIMENTAL
Intervention: RFS confirmed
Number of subjects: 967
Study 31895785 — intervention group
Group type: COMPARATOR
Intervention: No RFS
Number of subjects: 967
Study 29845770 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric exercise (10 sets of 10 repetitions at 40% of estimated one-repetition maximum leg press)
Number of subjects: 14
Study 29845770 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control period
Number of subjects: 14
Study 29845770 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric exercise
Number of subjects: 14
Study 27460201 — intervention group
Group type: EXPERIMENTAL
Intervention: Left high-frequency rTMS with quetiapine (n=12)
Number of subjects: 38
Study 27460201 — intervention group
Group type: EXPERIMENTAL
Intervention: Right low-frequency rTMS with quetiapine (n=13)
Number of subjects: 38
Study 27460201 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation with quetiapine (n=13)
Number of subjects: 38
Study 27460201 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall rTMS with quetiapine (all groups)
Number of subjects: 38
Study 24681270 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed bacterial lysate OM-85 BV (n=33)
Number of subjects: 68
Study 24681270 — intervention group
Group type: COMPARATOR
Intervention: Inactivated influenza vaccine (IIV) without OM-85 BV (n=35)
Number of subjects: 68
Study 22773391 — intervention group
Group type: EXPERIMENTAL
Intervention: Contemporaneous portal and arterial revascularization (CPAr)
Number of subjects: 80
Study 22773391 — intervention group
Group type: COMPARATOR
Intervention: Sequential portal and arterial revascularization (SPAr)
Number of subjects: 80
Study 19834330 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarpogrelate (oral) for 12 weeks
Number of subjects: 16
Study 19834330 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (Control group)
Number of subjects: 16
Study 18491099 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-source computed tomography (DSCT)
Number of subjects: 33
Study 18491099 — intervention group
Group type: COMPARATOR
Intervention: Coronary Angiography (CAG)
Number of subjects: 33
Study 18491099 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after DSCT
Number of subjects: 33
Study 16117986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir oral suspension 7 mg/kg q12h for 5 days
Number of subjects: 357
Study 12218521 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg valdecoxib
Number of subjects: 507
Study 12218521 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg valdecoxib
Number of subjects: 507
Study 12218521 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg valdecoxib
Number of subjects: 507
Study 12218521 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg valdecoxib
Number of subjects: 507
Study 12218521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 507
Study 10499776 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected patients
Number of subjects: 2
Study 10499776 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic HIV-positive patients
Number of subjects: 2
Study 8941460 — intervention group
Group type: EXPERIMENTAL
Intervention: s-HBOT
Number of subjects: 70
Study 2011701 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g sucralfate granulate given four times daily
Number of subjects: 60
Study 2011701 — intervention group
Group type: COMPARATOR
Intervention: 400 mg cimetidine twice daily
Number of subjects: 60
Study 6218781 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 59
Study 6218781 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 59
Study 29528175 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Monolithic Zirconia (MMZ)
Number of subjects: 40
Study 29528175 — intervention group
Group type: COMPARATOR
Intervention: Metal-Ceramic (MC)
Number of subjects: 40
Study 27150346 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation group (JCORES)
Number of subjects: 62
Study 27150346 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 62
Study 27151008 — intervention group
Group type: EXPERIMENTAL
Intervention: DICE regimen combined with rituximab
Number of subjects: 90
Study 27151008 — intervention group
Group type: COMPARATOR
Intervention: GDP regimen combined with rituximab
Number of subjects: 90
Study 25128022 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate
Number of subjects: 139
Study 25128022 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 139
Study 22435877 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox therapy
Number of subjects: 20
Study 22435877 — intervention group
Group type: EXPERIMENTAL
Intervention: Active malignancy or neutropenia at enrollment
Number of subjects: 20
Study 22435877 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary infection
Number of subjects: 20
Study 22435877 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline serum concentrations of iron and ferritin
Number of subjects: 20
Study 22435877 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical improvement during the first 14 days of study therapy
Number of subjects: 20
Study 22435877 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 30 clinical response
Number of subjects: 20
Study 19340492 — intervention group
Group type: EXPERIMENTAL
Intervention: EEGo monitor
Number of subjects: 21
Study 19340492 — intervention group
Group type: COMPARATOR
Intervention: BIS monitor
Number of subjects: 21
Study 17324976 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl plus magnesium sulphate (Group FM)
Number of subjects: 50
Study 17324976 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (Group F)
Number of subjects: 50
Study 15089024 — intervention group
Group type: EXPERIMENTAL
Intervention: STST group (static stretching, isolated progressive hamstring resistance exercise, and icing)
Number of subjects: 24
Study 15089024 — intervention group
Group type: EXPERIMENTAL
Intervention: PATS group (progressive agility and trunk stabilization exercises and icing)
Number of subjects: 24
Study 12032720 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen ophthalmic solution
Number of subjects: 408
Study 12032720 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 408
Study 12032720 — intervention group
Group type: COMPARATOR
Intervention: diclofenac
Number of subjects: 408
Study 9809141 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary stenting
Number of subjects: 129
Study 9809141 — intervention group
Group type: COMPARATOR
Intervention: Coronary stenting during coronary artery bypass graft
Number of subjects: 129
Study 7651474 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg of elemental zinc daily)
Number of subjects: 937
Study 2528425 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi Yangyin Huoxue prescription
Number of subjects: 68
Study 2528425 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 68
Study 1268617 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa (750 or 1000 mg)
Number of subjects: 0
Study 1268617 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term methyldopa treatment
Number of subjects: 0
Study 1268617 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa treatment for two to three weeks
Number of subjects: 0
Study 1268617 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged methyldopa treatment (mean 13.4 months)
Number of subjects: 0
Study 31368154 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorative yoga (1-hour guided group session followed by 4 weeks of at-home practice)
Number of subjects: 20
Study 31368154 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorative yoga (4 weeks of at-home practice)
Number of subjects: 20
Study 31368154 — intervention group
Group type: COMPARATOR
Intervention: Usual stress relief methods (4 weeks)
Number of subjects: 20
Study 28747208 — intervention group
Group type: EXPERIMENTAL
Intervention: Obinutuzumab (GA-101) consolidation therapy
Number of subjects: 188
Study 28747208 — intervention group
Group type: COMPARATOR
Intervention: No treatment (standard care)
Number of subjects: 188
Study 26562660 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy/leaflet
Number of subjects: 59
Study 26562660 — intervention group
Group type: COMPARATOR
Intervention: Leaflet
Number of subjects: 59
Study 24070911 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 83
Study 24070911 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 83
Study 21222131 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 LCPUFA (600 mg EPA and 400 mg DHA per day)
Number of subjects: 36
Study 21222131 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 LCPUFA (600 mg EPA and 400 mg DHA per day) + antioxidants (30 mg vitamin E, 60 mg vitamin C, 6 mg β-carotene)
Number of subjects: 36
Study 21222131 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 36
Study 18987031 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg
Number of subjects: 713
Study 18987031 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride 4 mg
Number of subjects: 713
Study 18987031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 713
Study 17854246 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone long‐acting injection (25 mg, 37.5 mg, or 50 mg every 2 weeks)
Number of subjects: 50
Study 17854246 — intervention group
Group type: COMPARATOR
Intervention: Oral risperidone (4 mg/day or less, 4-6 mg/day, or more than 6 mg/day)
Number of subjects: 50
Study 17854246 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone long‐acting injection (25 mg or 37.5 mg every 2 weeks)
Number of subjects: 50
Study 15701857 — intervention group
Group type: EXPERIMENTAL
Intervention: PemOx (pemetrexed 500 mg/m² plus oxaliplatin 120 mg/m²)
Number of subjects: 80
Study 15701857 — intervention group
Group type: EXPERIMENTAL
Intervention: PemCb (pemetrexed plus carboplatin AUC6)
Number of subjects: 80
Study 11892854 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of a brochure and videotape
Number of subjects: 149
Study 11892854 — intervention group
Group type: COMPARATOR
Intervention: Brochure alone
Number of subjects: 149
Study 11892854 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents with more accurate expectations
Number of subjects: 149
Study 11892854 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation procedures
Number of subjects: 149
Study 9535247 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg DTPwHB vaccine
Number of subjects: 120
Study 9535247 — intervention group
Group type: COMPARATOR
Intervention: 5 microg DTPwHB vaccine
Number of subjects: 120
Study 7805711 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg once a day (n = 10)
Number of subjects: 32
Study 7805711 — intervention group
Group type: EXPERIMENTAL
Intervention: Permixon 80 mg x 2 twice a day (n = 11)
Number of subjects: 32
Study 7805711 — intervention group
Group type: COMPARATOR
Intervention: Placebo once a day (n = 11)
Number of subjects: 32
Study 2683535 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day treatment with metronidazole and ampicillin
Number of subjects: 62
Study 2683535 — intervention group
Group type: COMPARATOR
Intervention: 4-day treatment with metronidazole and ampicillin
Number of subjects: 62
Study 30980691 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable tracker for 12 weeks, two group sessions, and a support phone call
Number of subjects: 68
Study 30980691 — intervention group
Group type: COMPARATOR
Intervention: Print materials describing physical activity guidelines
Number of subjects: 68
Study 28776894 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 μg/kg initial dose of activated eptacog beta (rhFVIIa)
Number of subjects: 27
Study 28776894 — intervention group
Group type: EXPERIMENTAL
Intervention: 225 μg/kg initial dose of activated eptacog beta (rhFVIIa)
Number of subjects: 27
Study 25015548 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal insufflation (NI) therapy
Number of subjects: 10
Study 25015548 — intervention group
Group type: COMPARATOR
Intervention: Continuous positive airway pressure (CPAP) therapy
Number of subjects: 10
Study 25015548 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported adherence
Number of subjects: 10
Study 23354313 — intervention group
Group type: EXPERIMENTAL
Intervention: Fit Body and Soul (FBAS)
Number of subjects: 604
Study 23354313 — intervention group
Group type: COMPARATOR
Intervention: Health-education comparison program
Number of subjects: 604
Study 22128654 — intervention group
Group type: EXPERIMENTAL
Intervention: Group prenatal care (GPC)
Number of subjects: 0
Study 22128654 — intervention group
Group type: COMPARATOR
Intervention: Individual prenatal care
Number of subjects: 0
Study 19339401 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat vegan diet
Number of subjects: 99
Study 19339401 — intervention group
Group type: COMPARATOR
Intervention: Conventional diabetes diet
Number of subjects: 99
Study 15562200 — intervention group
Group type: EXPERIMENTAL
Intervention: LAF237 (50 mg once daily, n=56)
Number of subjects: 107
Study 15562200 — intervention group
Group type: EXPERIMENTAL
Intervention: LAF237 (50 mg once daily, n=42)
Number of subjects: 107
Study 15562200 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=51)
Number of subjects: 107
Study 10411436 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic pouch
Number of subjects: 59
Study 10411436 — intervention group
Group type: COMPARATOR
Intervention: Side-to-end anastomosis
Number of subjects: 59
Study 7586947 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid
Number of subjects: 12
Study 7586947 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin alone (without probenecid)
Number of subjects: 12
Study 2274625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 6991095 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (IV 5‐FU) alone, 15 mg/kg/week
Number of subjects: 121
Study 6991095 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy: cyclophosphamide (15 mg/kg/week IV on day 1) plus 5-fluorouracil (15 mg/kg/week IV during weeks 2‐5)
Number of subjects: 121
Study 6991095 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (5-FU alone and combination therapy)
Number of subjects: 121
Study 6991095 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with pretreatment WBC greater than 12,000/mm3
Number of subjects: 121
Study 6991095 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretreatment lymphocyte count
Number of subjects: 121
Study 31791947 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK656
Number of subjects: 187
Study 29016381 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed tunnel endoscopic vein harvesting (n=100)
Number of subjects: 301
Study 29016381 — intervention group
Group type: EXPERIMENTAL
Intervention: Open tunnel endoscopic vein harvesting (n=100)
Number of subjects: 301
Study 29016381 — intervention group
Group type: COMPARATOR
Intervention: Open vein harvesting (n=101)
Number of subjects: 301
Study 25436448 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch‐up (ABC) intervention (n=54)
Number of subjects: 115
Study 25436448 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (n=61)
Number of subjects: 115
Study 23317441 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-midline-ports approach (Group 2)
Number of subjects: 100
Study 23317441 — intervention group
Group type: COMPARATOR
Intervention: French technique with three ports (Group 1)
Number of subjects: 100
Study 21553966 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐affirming questionnaire
Number of subjects: 278
Study 21553966 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐affirming implementation intention
Number of subjects: 278
Study 21553966 — intervention group
Group type: COMPARATOR
Intervention: Control questionnaire
Number of subjects: 278
Study 19184409 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17762738 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolization treatment for DAVFs
Number of subjects: 18
Study 17762738 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients with unruptured intracranial aneurysms)
Number of subjects: 18
Study 15479137 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (HF)
Number of subjects: 11
Study 15479137 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (LF)
Number of subjects: 11
Study 11700964 — intervention group
Group type: COMPARATOR
Intervention: Normal cornea examination using confocal microscope
Number of subjects: 120
Study 9512283 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 L PEG‐ELS
Number of subjects: 150
Study 9512283 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 L PEG‐ELS plus 296 mL magnesium citrate 1 hour prior
Number of subjects: 150
Study 9512283 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 L PEG‐ELS plus bisacodyl 20 mg
Number of subjects: 150
Study 7999653 — intervention group
Group type: EXPERIMENTAL
Intervention: L + F group (n = 27) - 38 mL of 1.5% lidocaine with 1/200,000 epinephrine and 100 micrograms of fentanyl
Number of subjects: 53